ALIM Alimera Sciences Inc

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that it will report second quarter 2019 financial results on Monday, July 29, 2019 after the market close.

Management will host a conference call at 9:00 AM ET on Tuesday, July 30, 2019 to review financial results and provide an update on corporate developments.  Following management’s formal remarks, there will be a question and answer session.

Participants are asked to pre-register for the call through the following link: http://dpregister.com/10131060. 

Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay.  Those without Internet access or who are unable to pre-register may dial in by calling 1-866-777-2509 (domestic) or 1-412-317-5413 (international).  All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://services.choruscall.com/links/alimera190430.html, which is also available through the company’s website at https://investor.alimerasciences.com/events-and-presentations.  A webcast replay of the call will be available approximately one hour after the end of the call through October 30, 2019.  The replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10131060. The telephonic replay will be available until September 13, 2019.

About Alimera Sciences, Inc.

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.

For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com

For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com